RxDoctor Payments Data

Karim Jamal, MD

Ophthalmology · Phoenix, AZNPI 1982759221

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,185 of the $71,648 with a category attached, or 60.3%. 22 manufacturers reported payments, led by Astellas Pharma US Inc at 33.0% of the total. 2025 is the largest year on record at $47,561, more than ten times the $471 reported in 2019. Among ophthalmology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$71,648in general payments, 2019–2025

Across 234 payments — averaging $306.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$24K
  • Regeneron Healthcare Solutions, Inc.$18K
  • Genentech USA, Inc.$8K
  • Alimera Sciences, Inc.$6K
  • Alcon$6K
  • Genentech, Inc.$6K
  • plus $5K from 16 others
$28,994in research payments, 2019–2025

Across 3 payments — averaging $9664.58 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Astellas Pharma Global Development$29K

What the payments were for

  • Consulting fees$12,46017%
  • Speaking & faculty fees$43,18560%
  • Travel & lodging$4,6957%
  • Food & beverage$11,26716%
  • Education$410%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$71,648 in reported general payments places this provider in the 95th percentile of 310 ophthalmology providers in Arizona.

See all ophthalmology providers in Arizona

Medicare billing

Part B allowed, 2024
$5,806,442
Medicare patients
912
Services billed
84,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate282$7,986
Brimonidine Tartrate40$2,042
Ofloxacin119$1,210
Ketorolac Tromethamine81$930
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat73$867
MoxifloxacinMoxifloxacin Hcl29$712
Atropine Sulfate19$654
Ciprofloxacin Hcl40$450
Timolol Maleate42$262
Latanoprost16$130

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →